Aesica Successfully Introduces Serialisation Services at Italian Finished Dose Manufacturing and Packaging Site
![](/46/pdcnewsitem/02/89/35/gyx9r82dkXZzgDn.jpg)
Aesica, the global pharmaceutical contract development and manufacturing organisation (CDMO), has successfully introduced serialisation services and initiated commercial production of two anti-allergy product lines for the Chinese market at its Pianezza site, Italy for a global, multinational client. The packaging lines and associated serialisation services are for the dedicated supply for one of Aesica’s strategic partners. The implementation took less than 6 months to complete, with the first production of serialisation batches just commenced.
The joint collaboration enabled the skills and unique knowledge of Aesica personnel at Pianezza to deliver serialisation packaging methods and processes that fully comply with stringent State Food and Drug Administration regulations set by the Ministry of Health of China and dovetailed with the partners coding requirements. As a consequence of the partnership, Pianezza is one of the first CDMOs in Italy to have successfully implemented serialisation for a pharmaceutical product.
The serialisation technology uses special digital techniques to check the linear barcode 128 and 20 digit serialised numbers. The code check is in full compliance with international ISO 15416 standards. The check system provides a reliable instrument for checking products and batches all the way through the packaging and distribution process.
The platform has capability for both thermal transfer and thermal ink jet printers for printing stickers with e-codes and variable data with 2D bar codes respectively. High quality variable programming, inks suitable for a multiplicity of applications and ribbons that comply with the latest legislative and environmental standards have all been part of the installation.
Paolo Pizzorni, Senior Director at Aesica Pianezza commented: “We are delighted that our strategic partnership model has seen the successful development of two robust serialisation packaging lines. For our customer this means improved patient safety with a reduced risk of competition from counterfeit products and the ability to detect expired drugs automatically. The end-users are now able to verify the integrity and authenticity of the products dispensed to patients using a simple scan.”
He continued: “China is a key geographic market that Western pharma companies seek to export to. At Aesica we are delighted to be providing serialisation services to enable one of our customers to meet the technical and complex serialisation regulations in this market.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance